Cargando…

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

BACKGROUND: Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration for locally advanced or metastatic urothelial cancer and lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karzai, Fatima, VanderWeele, David, Madan, Ravi A., Owens, Helen, Cordes, Lisa M., Hankin, Amy, Couvillon, Anna, Nichols, Erin, Bilusic, Marijo, Beshiri, Michael L., Kelly, Kathleen, Krishnasamy, Venkatesh, Lee, Sunmin, Lee, Min-Jung, Yuno, Akira, Trepel, Jane B., Merino, Maria J., Dittamore, Ryan, Marté, Jennifer, Donahue, Renee N., Schlom, Jeffrey, Killian, Keith J., Meltzer, Paul S., Steinberg, Seth M., Gulley, James L., Lee, Jung-Min, Dahut, William L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280368/ https://www.ncbi.nlm.nih.gov/pubmed/30514390 http://dx.doi.org/10.1186/s40425-018-0463-2

Ejemplares similares

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
por: Madan, Ravi A, et al.
Publicado: (2021)

A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2020)

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
por: Bilusic, Marijo, et al.
Publicado: (2022)

Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine
por: Madan, Ravi A., et al.
Publicado: (2023)

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
por: Abdul Sater, Houssein, et al.
Publicado: (2020)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
por: Gatti‐Mays, Margaret E., et al.
Publicado: (2019)

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
por: Zimmer, Alexandra S., et al.
Publicado: (2019)

Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute: Cancer Research and Care
por: Karzai, Fatima, et al.
Publicado: (2022)

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
por: Moutafi, Myrto, et al.
Publicado: (2023)

Nivolumab-associated acute glomerulonephritis: a case report and literature review
por: Jung, Kyungsuk, et al.
Publicado: (2016)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations
por: Thavaneswaran, Subotheni, et al.
Publicado: (2023)

Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report
por: Pastor, Danielle M., et al.
Publicado: (2020)

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
por: Strauss, Julius, et al.
Publicado: (2020)

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit
por: Tomita, Yusuke, et al.
Publicado: (2021)

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
por: Allen, Clint T., et al.
Publicado: (2019)

Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
por: Peinetti, Nahuel, et al.
Publicado: (2022)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
por: Chau, Vincent, et al.
Publicado: (2020)

Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report
por: Monge, Cecilia, et al.
Publicado: (2018)

Anti-angiogenesis in prostate cancer: knocked down but not out
por: Bilusic, Marijo, et al.
Publicado: (2014)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

A case report of multiple primary prostate tumors with differential drug sensitivity
por: Wilkinson, Scott, et al.
Publicado: (2020)

Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management
por: Marté, Jennifer L, et al.
Publicado: (2020)

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
por: Rosenberg, Jonathan E., et al.
Publicado: (2023)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma
por: DeMaria, Peter Joseph, et al.
Publicado: (2021)

Preliminary association of circulating tumor cells (CTCs) pre- and post-AdHER2 dendritic cell vaccination with overall survival in patients with metastatic HER2+ solid tumors
por: Tomita, Yusuke, et al.
Publicado: (2015)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Religious Communities and Human Flourishing
por: VanderWeele, Tyler J.
Publicado: (2017)

Religious Communities, Health, and Well-Being – Address to the US Air Force Chaplain
por: VanderWeele, Tyler J
Publicado: (2018)

The Interaction Continuum
por: VanderWeele, Tyler J.
Publicado: (2019)

Translation in fragile X: no home runs in the first at-bat
por: Veenstra-VanderWeele, Jeremy
Publicado: (2017)

Outcome-wide Epidemiology
por: VanderWeele, Tyler J.
Publicado: (2017)

Principles of confounder selection
por: VanderWeele, Tyler J.
Publicado: (2019)

Love of Neighbor During a Pandemic: Navigating the Competing Goods of Religious Gatherings and Physical Health
por: VanderWeele, Tyler J.
Publicado: (2020)

Constructed Measures and Causal Inference: Towards a New Model of Measurement for Psychosocial Constructs
por: VanderWeele, Tyler J.
Publicado: (2021)

Are Greenland, Ioannidis and Poole opposed to the Cornfield conditions? A defence of the E-value
por: VanderWeele, Tyler J
Publicado: (2021)

Viewpoint diversity in public health
por: VanderWeele, Tyler J.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sghdvbuaj4cfvfkjq2tj919prq